You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Ascelia Pharma: Interview with CEO Magnus Corfitzen
Interview with CEO Magnus Corfitzen about operational highlights and framework with timeline for rights issue of SEK 105m
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:20 AM 13-08-2024.